Rhabdomyolysis in a multiple myeloma patient secondary to concurrent treatment with lenalidomide and pravastatin and to lenalidomide alone

MeSH terms

• Amines / adverse effects
• Amines / therapeutic use
• Antineoplastic Combined Chemotherapy Protocols / therapeutic use
• Biomarkers
• Boronic Acids / administration & dosage
• Bortezomib
• Combined Modality Therapy
• Creatine Kinase, MM Form / blood
• Cyclohexanecarboxylic Acids / adverse effects
• Cyclohexanecarboxylic Acids / therapeutic use
• Dexamethasone / administration & dosage
• Drug Synergism
• Female
• Gabapentin
• Humans
• Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects*
• Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacokinetics
• Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
• Hypercholesterolemia / complications
• Hypercholesterolemia / drug therapy
• Immunologic Factors / administration & dosage
• Immunologic Factors / adverse effects*
• Immunologic Factors / pharmacokinetics
• Kidney Diseases / chemically induced
• Lenalidomide
• Melphalan / administration & dosage
• Middle Aged
• Multiple Myeloma / complications
• Multiple Myeloma / drug therapy*
• Multiple Myeloma / surgery
• Peripheral Blood Stem Cell Transplantation
• Polyneuropathies / complications
• Polyneuropathies / drug therapy
• Pravastatin / adverse effects*
• Pravastatin / pharmacokinetics
• Pravastatin / therapeutic use
• Pyrazines / administration & dosage
• Rhabdomyolysis / chemically induced*
• Thalidomide / administration & dosage
• Thalidomide / adverse effects
• Thalidomide / analogs & derivatives*
• Thalidomide / pharmacokinetics
• gamma-Aminobutyric Acid / adverse effects
• gamma-Aminobutyric Acid / therapeutic use